Editors' ChoiceCancer

PARP inhibitors need an extra STING for therapeutic efficacy

See allHide authors and affiliations

Science Translational Medicine  29 May 2019:
Vol. 11, Issue 494, eaax9557
DOI: 10.1126/scitranslmed.aax9557

Abstract

PARP inhibitors require the recruitment of CD8+ T cells through STING-cGAS signaling to maximize tumor regression.

View Full Text